Aromatic Amino Acid
Cross-indication landscape: approved drugs, active Phase 3, sponsors, and upcoming readouts.
About Aromatic Amino Acid
Aromatic Amino Acid drugs are a critical class of therapeutics primarily targeting neurological disorders by replenishing depleted neurotransmitters. The core mechanism involves providing precursors that the body converts into essential signaling molecules. For instance, levodopa, an aromatic amino acid, is converted into dopamine in the brain, a process vital for motor control. Carbidopa, often co-administered, inhibits the peripheral breakdown of levodopa, increasing its availability in the central nervous system and reducing side effects.
These agents are predominantly approved for Parkinson's Disease and Post-Encephalitic Parkinsonism, conditions characterized by a deficiency in dopamine. The journey of this class began with SINEMET, a combination of carbidopa and levodopa, first approved in 1975 by Merck, establishing the foundational treatment paradigm. Subsequent innovations have focused on improving delivery, efficacy, and patient convenience.
The field is currently characterized by a mature market for established therapies, with ongoing efforts to refine existing treatments and explore new formulations. While the core mechanism remains consistent, the evolution of Aromatic Amino Acid drugs reflects a continuous drive to enhance therapeutic outcomes for patients suffering from debilitating neurological conditions.
13 FDA-approved Aromatic Amino Acid drugs, including CREXONT, with 2 active Phase 3 trials. Explore approved drugs, the cross-indication pipeline, sponsors, and the Phase 3 readout calendar below.
Approved Aromatic Amino Acid Drugs
13 totalAromatic Amino Acid drugs, first introduced with SINEMET in 1975 by Merck, revolutionized Parkinson's disease treatment by providing levodopa, a precursor to dopamine. Carbidopa's inclusion was a key advancement, preventing peripheral levodopa metabolism and enhancing central nervous system delivery. Early iterations focused on oral formulations, but the class has evolved to include extended-release options and even specialized delivery systems to manage the fluctuating motor symptoms associated with Parkinson's disease. Differentiation among Aromatic Amino Acid therapies lies primarily in their formulation and delivery. SINEMET and its various STALEVO iterations (e.g., STALEVO 75, STALEVO 150) by ORION PHARMA offer different strengths of carbidopa and levodopa. RYTARY and DUOPA, approved in 2015 by IMPAX and AbbVie respectively, represent further refinements, with RYTARY offering an extended-release formulation and DUOPA providing a gel formulation for continuous intestinal infusion, addressing more complex motor fluctuations. INBRIJA, approved in 2018 by MERZ, offers an inhaled levodopa option for rapid symptom relief. Today, Aromatic Amino Acid therapies, particularly carbidopa/levodopa combinations, remain the gold standard first-line treatment for Parkinson's disease. The market is heavily influenced by generic competition for older formulations, though newer, patented formulations like RYTARY and DUOPA cater to specific patient needs for improved symptom control. The introduction of INBRIJA provides an alternative for managing 'off' episodes. The class-wide safety profile is well-understood, with the primary challenge being the management of motor fluctuations and dyskinesias over time.
Methodology
Approved drugs sourced from FDA `pharmClassEpc` (Established Pharmacologic Class) labeling. Active industry trials matched by intervention name (brand or generic) — same coverage approach as our target pages, with the same limitation: pre-approval candidates using development codes won't match until they're approved.
"Active" = RECRUITING / ACTIVE_NOT_RECRUITING / NOT_YET_RECRUITING. Sponsor counts include any company running at least one active industry trial.